Regenerative Medical Technology (RMTG) Return on Capital Employed (2019 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Return on Capital Employed of 2.31% for Q1 2026, up 355.0% year-over-year from 0.51% in Q1 2025, and down 13.96% quarter-over-quarter from 2.68% in Q4 2025.
Regenerative Medical Technology (RMTG) Return on Capital Employed (2019 - 2026) Analysis & Trends
Regenerative Medical Technology's Return on Capital Employed history runs 8 years deep, the most recent figure standing at 2.31% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 355.0% year-over-year to 2.31%; the TTM figure through Mar 2026 stood at 2.31% (up 355.0% YoY), while the FY2025 annual figure was 2.65%, up 297.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 2.31%, down from 2.68% in the prior quarter.
- The five-year high for Return on Capital Employed was 91.76% in Q4 2022, with the low at 309.64% in Q2 2022.
- The 5-year median for Return on Capital Employed is 2.27% (2024), against an average of 22.39%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed plunged 33359 bps in 2022, then jumped 36270 bps in 2023.
- Regenerative Medical Technology's Return on Capital Employed stood at 91.76% in 2022, then plunged by 96 bps to 3.73% in 2023, then slumped by 109 bps to 0.32% in 2024, then soared by 941 bps to 2.68% in 2025, then declined by 14 bps to 2.31% in 2026.
- Business Quant data shows RMTG's Return on Capital Employed at 2.31% in Q1 2026, 2.68% in Q4 2025, and 1.41% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | 2.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.31% |
| Dec 31, 2025 | 2.68% |
| Sep 30, 2025 | 1.41% |
| Jun 30, 2025 | -1.08% |
| Mar 31, 2025 | -1.24% |
| Dec 31, 2024 | -0.32% |
| Sep 30, 2024 | 1.78% |
| Jun 30, 2024 | 2.27% |
| Mar 31, 2024 | 3.49% |
| Dec 31, 2023 | 3.73% |
| Sep 30, 2023 | 15.98% |
| Jun 30, 2023 | 53.06% |
| Mar 31, 2023 | 63.02% |
| Dec 31, 2022 | 91.76% |
| Sep 30, 2022 | -70.43% |
| Jun 30, 2022 | -309.64% |
| Mar 31, 2022 | -239.36% |
| Dec 31, 2021 | -110.62% |
| Sep 30, 2021 | -261.39% |
| Jun 30, 2021 | -11.78% |